Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta‐analysis

Reviews in Medical Virology - Tập 29 Số 3 - 2019
Mohamed Zuhair1, G. Suzanne A. Smit2,3,4, Gabriel Wallis1, Faiz Jabbar1, Colette Smith5, Brecht Devleesschauwer6, Paul Griffiths1,5
1Department of Virology, Royal Free NHS Foundation Trust, London, UK
2Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Ghent, Belgium
3Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium
4Instituut of Tropical Medicine (ITM), Antwerp, Belgium
5Institute for Global Health, University College London, London, UK
6Department of Public Health and Surveillance, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium

Tóm tắt

Summary

Cytomegalovirus (CMV) infection does not usually produce symptoms when it causes primary infection, reinfection, or reactivation because these three types of infection are all controlled by the normal immune system. However, CMV becomes an important pathogen in individuals whose immune system is immature or compromised, such as the unborn child. Several vaccines against CMV are currently in clinical trials that aim to induce immunity in seronegative individuals and/or to boost the immunity of those with prior natural infection (seropositives). To facilitate estimation of the burden of disease and the need for vaccines that induce de novo immune responses or that boost pre‐existing immunity to CMV, we conducted a systematic survey of the published literature to describe the global seroprevalence of CMV IgG antibodies. We estimated a global CMV seroprevalence of 83% (95%UI: 78‐88) in the general population, 86% (95%UI: 83‐89) in women of childbearing age, and 86% (95%UI: 82‐89) in donors of blood or organs. For each of these three groups, the highest seroprevalence was seen in the World Health Organisation (WHO) Eastern Mediterranean region 90% (95%UI: 85‐94) and the lowest in WHO European region 66% (95%UI: 56‐74). These estimates of the worldwide CMV distribution will help develop national and regional burden of disease models and inform future vaccine development efforts.

Từ khóa


Tài liệu tham khảo

10.1002/path.4437

10.1016/S0140-6736(00)02350-3

Institute of Medicine Committee to Study Priorities for Vaccine Development, 2000, Vaccines for the 21st Century: A Tool for Decisionmaking

10.1086/421999

10.1002/rmv.1921

Revello MG, 2011, Role of prenatal diagnosis and counseling in the management of 735 pregnancies complicated by primary human cytomegalovirus infection: a 20‐year experience, JClinVirol, 50, 303

10.1016/j.ajog.2006.08.039

10.1001/jama.1989.03420240121038

10.1182/blood-2003-10-3616

10.1056/NEJMoa1706640

10.1016/S0140-6736(04)16500-8

10.1086/379077

10.1371/journal.pone.0016103

10.1093/cid/cit083

10.1007/s40265-016-0653-5

10.7326/0003-4819-151-4-200908180-00135

10.1086/652438

Nations U.World Population Prospects: The 2017 Revision2017.https://www.un.org/development/desa/publications/world‐population‐prospects‐the‐2017‐revision.html.

Buerkner PC, 2016, brms: an R package for Bayesian multilevel models using Stan, J Stat Softw, 80, 1

Team RC.R: a language and environment for statistical computing R Foundation for Statistical Computing Vienna Austria;2017.https://www.R‐project.org.

10.1002/rmv.655

10.1371/journal.pone.0081881

10.1002/rmv.695

10.1002/rmv.659

10.1002/rmv.1744

10.1002/rmv.535

10.1056/NEJMoa0804749

10.1093/infdis/jir138

10.1016/S0140-6736(84)90930-9

10.1016/S0140-6736(86)92315-9

10.1016/S1473-3099(11)70344-9

10.1093/infdis/jiv515

10.1089/aid.2016.0121

10.1111/j.1471-0528.1984.tb05915.x